We're pleased to announce that Omic has grown to 15 employees and is accelerating our pipeline programs toward clinical development—all while remaining a bootstrapped, profitable company.

## Seven Years of Progress

Since founding Omic in 2017, we've built something unprecedented:

- **AI Scientist platform** that achieves 93.3% on GPQA-Diamond (highest of any AI system)
- **Digital Patient technology** with 82% accuracy predicting clinical trial outcomes
- **4 pipeline programs** across oncology, infectious disease, hematology, and cardiovascular disease
- **Enterprise platform** now serving researchers worldwide
- **Profitable operations** funding our own growth

## Pipeline Advancement

Our growing revenue allows us to invest significantly in advancing our most mature programs toward the clinic:

### ONC-001 (Oncology - ICI Resistance)

- Development candidate nominated
- IND-enabling studies underway
- Phase 1 trial planned for 2025

### HEM-001 (Hematology - Sickle Cell)

- Lead series optimized
- Development candidate selection imminent
- Regulatory strategy defined

Both programs could have drugs in human testing within the next 18 months—funded entirely by our platform revenue and partnerships.

## Platform Scale

We're also investing heavily in our AI platform:

- **Compute infrastructure**: Expanding capacity for larger-scale AI training
- **Data partnerships**: Integrating additional multi-omics datasets
- **AI research**: Advancing next-generation reasoning capabilities
- **Enterprise features**: Building tools for large pharma deployment

## The Bootstrapped Advantage

Reaching this scale as a bootstrapped company is unusual in biotech—but we believe it's the right approach for drug discovery:

- **Long-term thinking**: We can pursue 10-year programs without quarterly pressure
- **Scientific focus**: Our decisions are driven by science, not investor timelines
- **Sustainable economics**: We don't need exits or IPOs to succeed
- **Aligned incentives**: We succeed only if our drugs succeed

## Team Growth

We've grown from 2 founders to 15 employees, with deep expertise across:

- **AI/ML research** \- Pushing the frontier of scientific reasoning
- **Computational biology** \- Translating biology into computable models
- **Drug discovery** \- Experienced pharmaceutical scientists
- **Engineering** \- Building scalable, production systems

Our lean team reflects the power of AI-augmented drug discovery—we achieve more with fewer people by letting our AI Scientists handle the computational heavy lifting.

## What's Next

We're now at an inflection point. We've proven the technology works. We've built a real pipeline. We're generating revenue that funds continued growth.

The next chapter is taking our AI-discovered drugs into human trials—proving that a bootstrapped AI company can go all the way from target discovery to clinical validation.